TABLE III.
Kaplan-Meier point estimates of progression-free and overall survival
| Overall (n=212) | Setting of Crizotinib Initiation (n=210)a | ||
|---|---|---|---|
|
| |||
| First-Line (n=137) | Second- or Later-Line (n=73) | ||
| Progression-free survival | |||
| Time (months) to progression or death from crizotinib initiation | |||
| Mean (SE) | 9.8 (0.4) | 9.9 (0.5) | 9.2 (0.7) |
| Median (95% CI) | 9.5 (8.7, 10.1) | 9.6 (8.6, 10.2) | 9.0 (7.7, 10.6) |
| Q1, Q3 | 6, 12 | 6, 13 | 6, 11 |
| Overall survival | |||
| Time (months) to death from crizotinib initiation | |||
| Mean (SE) | 19.8 (0.5) | 20.0 (0.6) | 16.6 (0.7) |
| Median (95% CI) | 23.4 (19.5, —) | 23.4 (18.3, —) | — (15.1, —) |
| Q1, Q3 | 14, — | 15, — | 12, — |
| 1- and 2-year survival rates | |||
| Percent still alive at 1 year after crizotinib initiation (95% CI) | 81.9 (76.6–87.1) | 84.9 (78.8–91.0) | 75.9 (65.9– 85.9) |
| Percent still alive at 2 years after crizotinib initiation (95% CI) | 49.1 (39.2–59.0) | 47.2 (34.7–59.7) | 50.4 (35.1– 65.7) |
SE = standard error; CI = confidence interval; Q1 = 1st quartile; Q3 = 3rd quartile.
a
Line of crizotinib initiation was unknown for 2 patients